摘要
To the Editor:Psoriasis is a chronic autoimmune inflammatory disease that has a significant negative impact on quality of life.Interleukin(IL)-17A,a key molecule in the T helper 17 pathway,is important in the pathogenesis of psoriasis.Secukinumab,a fully human immunoglobulin G1 kappa monoclonal antibody that targets IL-17A,was the first anti-IL-17A antibody approved by the US Food and Drug Administration in 2015.In China,it was approved in March 2019 for the treatment of moderate to severe psoriasis vulgaris(PsV),whereas in Japan,it is not only used for PsV but also psoriatic arthritis and generalized pustular psoriasis(GPP).The safety and efficacy of secukinumab have been assessed in four randomized controlled trials(RCTs)(ERASURE,FEATURE,JUNCTURE,and FIXTURE),which showed the superiority of secukinumab compared with placebo,etanercept,and ustekinumab,with long-term persistence of the clearance rate.However,the real-world setting of clinical practice is different from the strictly regulated setting of RCTs,which are conducted in only selected patients that fulfill strict inclusion and exclusion criteria to maximize internal validity.To date,there have been no official English reports of real-world studies published in China.
